Cite
MLA Citation
A.M. Oza et al.. “2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC).” European journal of cancer, vol. 51, n.d., pp. S532–. http://access.bl.uk/ark:/81055/vdc_100030628262.0x00003a